Comparison of the ELISA and ECL Assay for Vedolizumab Anti-drug Antibodies: Assessing the Impact on Pharmacokinetics and Safety Outcomes of the Phase 3 GEMINI Trials.

AAPS J · 2020 · PMC7669784 · PMID 33200296

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

The results of vedolizumab CL L covariate analyses were consistent with previous reports ( 12 ) and showed a trend for body weight and serum albumin to affect CL L , although the difference only reached clinical relevance (± 25%) at the lowest albumin concentration.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.